Penny stocks: should I buy Supply@Me (SYME) shares?

Supply@Me Capital shares are trading at 0.39p, but this UK penny stock is targeting an addressable market of inventory under management in the trillions of dollars!

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

When I look at penny stocks, I’m always especially minded to ask the first question Warren Buffett and Charlie Munger ask when weighing up a company. Namely, “What could go wrong?”

Peter Bevelin, author of Seeking Wisdom: From Darwin to Munger, has put the ultimate answer in a nutshell: “If a catastrophic outcome is possible or you can’t judge the downside, stay away.”

With this in mind, I’ve asked myself whether I should buy UK penny stock Supple@Me Capital (LSE: SYME). I’ll say straight off that I’ve concluded I should avoid it. Here, I’ll explain my reasons for steering clear and also look at the potential upside, if my caution is misconceived.

Empty platform

Supply@Me Capital has developed a fintech platform. It aims to bring together companies wishing to raise cash against their inventories with funders willing to supply it. This at a cost that makes a profit for both the funders and Supply@Me.

The company gained a stock market listing in March 2020. It targeted a first securitisation of inventories via its platform within six months. But, so far, it hasn’t managed to bring together a single deal.

A £227m penny stock

I’ve previously been sceptical about Supply@Me’s prospects. For one thing, I’m not convinced the company’s business model is actually viable. And there are a number of other things that concern me.

First, Supply@Me was sold to investors on a prospectus showing net assets of £227m — bang in line with its market capitalisation at an issue price of 0.7p a share. However, on its post-listing balance sheet, net assets were less than £1m. Goodwill had been entirely written off.

Waiting for Godot

As well as the repeated delays to a first securitisation of inventories, the publication of this penny stock’s first audited financial statements has been put back and back. First, because the company has twice changed the date of its financial year-end. And second, because it’s simply failed to get the results out by the dates it’s set.

On 19 January, Supply@Me told us the results would be “published in April.” On 23 April, it put the date back to “during May.” On 26 May, it said the statements “are being finalised, with publication expected next week” (i.e. during the trading week ending 4 June). And on 4 June, it announced another delay. It said it will publish the results only after it’s secured a new funding facility “expected to be completed in the coming days.

In view of the net assets carry-on, and the repeated delays to both the first securitisation of inventories and first audited results, Supply@Me doesn’t pass my ‘smell test’. I’d want to at least see those audited results before going anywhere near this penny stock. But what if my scepticism is misconceived?

A penny stock high-flier?

Supply@Me shares are trading at 0.39p, as I’m writing. At this price, the market capitalisation of the company is £128m.

This may look high for a start-up business, but if the company really has found a way to revolutionise inventory monetisation through its fintech platform, the market opportunity could be vast. Supply@Me talks of an addressable market of inventory under management in the $trillions. Not a bad target for a little UK penny stock!

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »